marked.bio

Company

AskGene Pharma

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

tislelizumab 2sintilimab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

    Active, not recruiting Phase 3 AskGene Pharma Started 2024Primary completion 2026-12 NCT06206733

    ASKB589oxaliplatincapecitabinetislelizumab

    CLDN 18.2 positive

    Claudin 18.2 expressionGastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

  2. ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

    Active, not recruiting Phase 1/2 AskGene Pharma Started 2023Primary completion 2025-10 NCT05632939

    CAPOXsintilimabtislelizumab

    Tumor tissue samples are CLDN18.2 positive detected by central laboratory

    Claudin 18.2 expressionGastric Cancer, Gastroesophageal Cancer (GC)